Orthobiologics for Knee Osteoarthritis: Fact, Fiction, or Fantasy?
Bert R. Mandelbaum, MD, DHL (Hon)
December 17, 2018
Faced with both exciting new research and dangerous hype about such treatments
as platelet-rich plasma and stem cells for
osteoarthritis of the knee, I've begun to adopt what I call the Orthobiological Surgeon's
Prayer: I ask for the ability to help when I can, the judgment to know
when I can and cannot help, and the wisdom to know the difference.
Among the many biological substances that might help chondroprotection
and chondrofacilitation, platelet-rich plasma and hyaluronic acid injections
are supported by early and significant evidence. It's too early yet
to make confident use of stem cells or amniotic fluid, and we must warn
patients to be particularly careful about claims for these substances.
Such claims are coming fast and furious as unscrupulous businesses keep
popping up to exploit patients' desperation and confusion and the
gap between hope and knowledge, even as the US Food and Drug Administration
(FDA) attempts to clamp down on them. That makes it particularly important
for clinicians to understand the fast-moving science behind them.
But eventually, I believe, the science will triumph over quackery, and
orthobiologics will become an essential part of every knee surgeon's
armamentarium.
It's important to remember that the FDA grants exemptions under section
361 of the Public Health Service Act for human cell, tissues, and cellular
and tissue-based products only for homologous use and only if they are
minimally manipulated.[1]
Even within those parameters, what most specialty stem cell clinics are
offering is a lot of snake oil. But eventually, I believe, the science
will triumph over quackery and orthobiologics will become an essential
part of every knee surgeon's armamentarium.
The development of these treatments corresponds to other trends in medicine,
including personalization, artificial intelligence, 3D printing, and robotics.
It's possible to imagine the day when we can tailor a treatment to
the precise genetic and anatomical needs of a particular patient.
Orthobiologics may already be approaching a tipping point when they become
part of the mainstream. This trend follows the trajectory that orthopedics
has already begun. We are moving away from the day when we just cut bones
and moved them into place. We are now considering the knee as an organ
and taking into account alignment; meniscal and ligament deficiency; and
molecular, tissue, and matrix issues.
Cartilage tissue engineering in particular requires an understanding of
these various components at several length scales. Performance is generally
measured in meters. The organ is measured in centimeters. Tissue is measured
in millimeters.
As surgeons, we must work on all these scales. Our treatments are only
as strong as their weakest links. Likewise, whether an acute knee injury
results in osteoarthritis depends on a "perfect storm" of factors,
including the athlete's age and gender; the level of play; the age
of the injury; the timing of the treatment; and modulators, such as matrix
metalloproteinases and glycosaminoglycan (GAG).[2]
We must take all these factors into consideration not only in our treatment
plans but in working to prevent injuries. To paraphrase a comment from
the hero of the book and movie
The Martian, "In the face of overwhelming odds, I'm left with only one option:
I'm gonna have to science the heck out of it."[3]
That science begins with the understanding that successful tissue engineering
must include cells, growth factors and cytokines, scaffolds, and biomaterials.
It's like a construction site: In addition to the workers, if you
don't have both rebar and concrete, your walls won't stand.
Personalizing Orthobiologics
But it's not yet clear exactly which orthobiologics are needed for
which project of regeneration. The list available to us now includes glucosamine-chondroitin
sulfate, hyaluronic acid, platelet-rich plasma, cytokine modulation (such
as interleukin-1 receptor agonist [IL-1ra] inhibition of inflammation),
stem cells (of multiple origins), and amniotic fluid.
A monosaccharide precursor to GAG, glucosamine-chondroitin appears to increase
polyglycan production, decrease degradative enzymes, and inhibit interleukin-1
beta and tumor necrosis factor alpha as well as other inflammatory agents,
while increasing GAG content and cartilage thickness after injury.[4,5] Multiple randomized controlled trials have shown that it can improve measures
of joint pain and function, such as Knee injury and Osteoarthritis Outcome Score[6] and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores.[7]
Hyaluronic acid appears to help polyglycans and GAG bind to collagen mesh
and aid in hydration, decreasing the inflammatory response, improving
the cartilage viscoelastic properties, and slowing degeneration.[8] Dozens of trials have shown that it can beat placebo[9] and match nonsteroidal anti-inflammatory drugs or corticosteroids[10] in relieving symptoms of osteoarthritis of the knee. They also suggest
that it is well-tolerated and safe.[11]
Platelet-rich plasma owes its benefits to the 1507 proteins in
platelets. These include growth factors that stimulate cell growth, recruitment,
differentiation, and gene expression; skin closure; cytokine secretion;
blood vessel and collagen synthesis; growth inhibition; apoptosis, angiogenesis;
mitogenesis; and chemotaxis.[12]
In clinical trials, platelet-rich plasma has enhanced superficial zone
protein secretion from the synovium and cartilage.[13] It, too, has improved WOMAC scores over 6 months in randomized, controlled
clinical trials of osteoarthritis of the knee.[14,15] That said, platelet-rich plasma is very complex, and its biological effects
can vary with age, body mass index, nonsteroidal anti-inflammatory drugs,
even diet.[12]
Autologous IL-1ra in theory stimulates the synthesis of anti-inflammatory
cytokines. In early trials, it looks as if it may not have as robust an
effect as platelet-rich plasma, particularly because it does not act on
stem cells.[16]
These treatments may have a synergistic approach. For example, hyaluronic
acid induces the release of growth factors from platelet-rich plasma.[15]
Stem cells come in many varieties: adipose derived, bone marrow aspirate
concentrate, allogeneic, and induced pluripotential. There are only a
handful of small studies looking at any of these in osteoarthritis of
the knee. What's been done so far looks promising,[17] but some of these sources, such as bone marrow aspirate, can be very invasive.
Amniotic fluid provides another potential source of stem cells. These cells
can be expanded in vitro into osteogenic, myogenic, adipogenic, endothelial,
hepatic, and neurogenic cells. This literature is even more preliminary,
though a registry study suggests improvements in patients with osteoarthritis.[18]
If we categorize these approaches by traffic light, we'd give amniotic
fluid and glucosamine/chondroitin a yellow light because of the limited,
but positive, evidence. Bone marrow aspirate and cytokine modulation would
get a red light, because the evidence is even more limited. The green
lights would go to platelet-rich plasma and hyaluronic acid, because of
the relatively large database.
When it comes to biologic adjuvants for
anterior cruciate ligament repair, the story is different. We'll explore those issues in the
next column.
References
-
Regulatory considerations for human cells, tissues, and cellular and tissue-based
products: minimal manipulation and homologous use. US Food and Drug Administration.
December 2017.
Source Accessed November 7, 2018.
- Rai MF, Brophy RH, Sandell LJ. Osteoarthritis following meniscus and ligament
injury. Curr Opin Rheumatol. 2019;31:70-79. doi:10.1097/bor.0000000000000566
-
The Martian. 2015. IMDb.
Source Accessed November 7, 2018.
- Shikhman AR, Kuhn K, Alaaeddine N, Lotz M. N-acetylglucosamine prevents
IL-1-mediated activation of human chondrocytes. J Immunol. 2001;166:5155-5160.
doi:10.4049/jimmunol.166.8.5155
- Lippiello L, Woodward J, Karpman R, Hammad TA. In vivo chondroprotection
and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop
Relat Res. 2000;229-240. doi:10.1097/00003086-200012000-00027
- Braham R, Dawson B, Goodman C. The effect of glucosamine supplementation
on people experiencing regular knee pain. Br J Sports Med. 2003;37:45-49.
doi:10.1136/bjsm.37.1.45
- Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine
sulphate on osteoarthritis progression: a randomised, placebo-controlled
clinical trial. Lancet. 2001;357:251-256. doi:10.1016/s0140-6736(00)03610-2
- Hardingham T, Muir H. The specific interaction of hyaluronic acid with
cartilage proteoglycans. Biochim Biophys Acta Gen Subj. 1972;279:401-405.
doi:10.1016/0304-4165(72)90160-2
- Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with Hylan
G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic
knee. Clin Ther. 1998;20:410-423. doi:10.1016/s0149-2918(98)80052-0
- Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of
hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic
review and meta-analysis. Semin Arthritis Rheum. 2014;43:593-599. doi:10.1016/j.semarthrit.2013.10.002
- Bannuru RR, Osani M, Vaysbrot EE, McAlindon TE. Comparative safety profile
of hyaluronic acid products for knee osteoarthritis: a systematic review
and network meta-analysis. Osteoarthr Cartil. 2016;24:2022-2041. doi:10.1016/j.joca.2016.07.010
- Akeda K, An HS, Okuma M, et al. Platelet-rich plasma stimulates porcine
articular chondrocyte proliferation and matrix biosynthesis. Osteoarthr
Cartil. 2006;14:1272-1280. doi:10.1016/j.joca.2006.05.008
- Sakata R, McNary SM, Miyatake K, et al. Stimulation of the superficial
zone protein and lubrication in the articular cartilage by human platelet-rich
plasma. Am J Sports Med. 2015;43:1467-1473. doi:10.1177/0363546515575023
- Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich
plasma is more effective than placebo for knee osteoarthritis. Am J Sports
Med. 2013;41:356-364. doi:10.1177/0363546512471299
- Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid,
hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World
J Orthop. 2014;5:351-361. doi:10.5312/wjo.v5.i3.351
- Auw Yang KG, Raijmakers NJ, van Arkel ER, et al. Autologous interleukin-1
receptor antagonist improves function and symptoms in osteoarthritis when
compared to placebo in a prospective randomized controlled trial. Osteoarthr
Cartil. 2008;16:498-505. doi:10.1016/j.joca.2007.07.008
- Vega A, Martín-Ferrero MA, Del Canto F, et al. Treatment of knee
osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized
controlled trial. Transplantation. 2015;99:1681-1690. doi:10.1097/tp.0000000000000678
-
Demesmin D, Beall D, Nalamachu S. Amniotic fluid as a homologue to synovial
fluid: interim analysis of prospective, multi-center outcome observational
cohort registry of amniotic fluid treatment for osteoarthritis of the
knee. Program and abstracts of the American Academy of Pain Medicine 57th
Annual Meeting and Exhibition; July 12-16, 2015; Anaheim, California.
Source Accessed November 7, 2018.
Medscape Orthopedics © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily
reflect the views of WebMD or Medscape.
Cite this article: Orthobiologics for Knee Osteoarthritis: Fact, Fiction,
or Fantasy? -
Medscape - Dec 17, 2018.